NLM Digital Collections

Search

Start Over Subjects Drug Costs ✖Remove constraint Subjects: Drug Costs Publication Year 2015 to 2016 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2015">2015</span> to <span class="to" data-blrl-end="2016">2016</span>

1. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia

Author(s):
Doshi, Jalpa A., author
Li, Pengxiang, author
Huo, Hairong, author
Pettit, Amy R., author
Kumar, Rishab, author
Weiss, Brendan M., author
Huntington, Scott F., author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, 2016
Subject(s):
Cost Sharing
Drug Costs
Medicare Part D -- economics
Financing, Personal
Health Services Accessibility
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
Protein Kinase Inhibitors -- economics
Protein Kinase Inhibitors -- therapeutic use
Protein-Tyrosine Kinases -- antagonists & inhibitors
Humans
United States

2. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Cunningham, Courtney, author
Pearson, Steven D., author
Kazi, Dhruv S., author
Coxson, Pamela G., author
Moran, Andrew E., author
Penko, Joanne, author
Guzman, David, author
Bibbins-Domingo, Kirsten, author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, November 24, 2015
Subject(s):
Anticholesteremic Agents -- therapeutic use
Azetidines -- therapeutic use
Enzyme Inhibitors -- therapeutic use
Hypercholesterolemia -- therapy
Hyperlipoproteinemia Type II -- prevention & control
Proprotein Convertases -- economics
Serine Endopeptidases -- economics
Cholesterol, LDL
Cost-Benefit Analysis
Decision Support Techniques
Drug Costs
Drug Resistance
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Technology Assessment, Biomedical
Treatment Outcome
Value-Based Purchasing
Humans
New England
United States

3. CardioMEMS (tm) HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto (tm), Novartis AG) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Ollendorf, Daniel A., author
Ollendorf, Daniel A., author
Tarlochan Sandhu, Alexander, author
Chapman, Rick, author
Heidenreich, Paul A., author
Russo, Elizabeth, author
Shore, Karen K., author
Synnott, Patricia, author
Travers, Karin, author
Weissberg, Jed, author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, December 1, 2015
Subject(s):
Angiotensin II Type 1 Receptor Blockers -- administration & dosage
Antihypertensive Agents -- administration & dosage
Blood Pressure Monitoring, Ambulatory -- instrumentation
Blood Pressure Monitoring, Ambulatory -- methods
Heart Failure -- diagnosis
Heart Failure -- drug therapy
Neprilysin -- administration & dosage
Tetrazoles -- administration & dosage
Valsartan -- administration & dosage
Angiotensin II Type 1 Receptor Blockers -- economics
Antihypertensive Agents -- economics
Cost-Benefit Analysis
Drug Combinations
Drug Costs
Neprilysin -- antagonists & inhibitors
Neprilysin -- economics
Outcome and Process Assessment (Health Care)
Tetrazoles -- economics
Valsartan -- economics
Humans
United States

4. Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit

Author(s):
Pearson, Steven D., author
Dreitlein, Bill, author
Henshall, Chris, author
Publication:
Boston, MA : Institute for Clinical and Economic Review, March 2016
Subject(s):
Drug Costs
Economics, Pharmaceutical
Insurance, Pharmaceutical Services -- economics
Prospective Payment System
Reimbursement Mechanisms -- economics
Cost Savings
Cost Sharing
Formularies
Medicaid -- economics
Medicare -- economics
Off-Label Use -- economics
Pilot Projects
Value-Based Purchasing
Humans
United States